8-K: CytoSorbents Reschedules Earnings Release, Reaffirms Preliminary Financial Expectations

CytoSorbents Corporation announced a rescheduled earnings call for Q4 and full-year 2024, while reaffirming previously disclosed preliminary financial expectations and progress on DrugSorb-ATR regulatory submissions.

Summary

• CytoSorbents Corporation has rescheduled its Q4 and full-year 2024 earnings call to March 31, 2025, to allow more time for the annual audit.
• The company reaffirms its preliminary financial expectations for the quarter and year ended December 31, 2024.
• Fourth quarter product revenue is expected to be in the range of $9.0 million to $9.2 million, representing 22% to 25% growth compared to $7.35 million in Q4 2023.
• Full-year product revenue is expected to be in the range of $35.4 million to $35.6 million, representing approximately 14% growth compared to $31.1 million for the full-year 2023.
• Fourth quarter product gross margin is expected to be approximately 70%, compared to 61% in the prior quarter and 72% in Q4 2023.
• The company continues to expect regulatory decisions on DrugSorb-ATR marketing applications from the U.S. FDA and Health Canada in 2025.
• The pro forma cash balance on December 31, 2024, after giving effect to the Rights Offering and the exercise of Series A Right Warrants, would have been approximately $17.0 million, including unrestricted cash of approximately $15.5 million.
• Net cash used in the fourth quarter of 2024 was approximately $2.5 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The reaffirmation of financial expectations and progress on DrugSorb-ATR are positive signals. However, the delay in the earnings call and the slight decrease in gross margin compared to the previous year temper the overall outlook.

Positives

• The company reaffirms its preliminary financial expectations for Q4 and full-year 2024.
• Expected revenue growth of 22-25% in Q4 and approximately 14% for the full year.
• DrugSorb-ATR marketing applications are still under review with the FDA and Health Canada.
• The company raised $7.85 million in gross proceeds in Q1 2025, strengthening its financial position.

Negatives

• The earnings call was rescheduled due to delays in completing the annual audit.
• Q4 product gross margin is expected to be approximately 70%, compared to 72% in Q4 2023.

Risks

• The estimated financial results, proforma cash balance and estimate of cash utilized in the fourth quarter remain preliminary and unaudited.
• The company's actual results, events and performance could differ materially from those in the forward-looking statements.

Future Outlook

The company expects regulatory decisions on DrugSorb-ATR marketing applications from the U.S. FDA and Health Canada in 2025.

Management Comments

• The Company continues to expect regulatory decisions on DrugSorb-ATR marketing applications in 2025.

Industry Context

CytoSorbents operates in the blood purification market, focusing on critical care and cardiac surgery applications. The company's technologies compete with other blood purification methods and aim to address unmet needs in treating life-threatening conditions.

Stakeholder Impact

• Shareholders: Reaffirmation of financial expectations provides some reassurance, but the earnings call delay may cause concern.
• Employees: Continued progress on product development and revenue growth is generally positive for employee morale.
• Customers: Potential approval of DrugSorb-ATR could provide a new treatment option for patients at risk of bleeding during surgery.
• Suppliers: Increased revenue could lead to higher demand for supplies and services.
• Creditors: A stronger financial position reduces credit risk.

Next Steps

• The company will report fourth quarter and full year 2024 financial results and file its Form 10-K after the market close on Monday, March 31, 2025.
• Management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30PM ET on March 31, 2025.
• The company awaits regulatory decisions on DrugSorb-ATR marketing applications from the U.S. FDA and Health Canada in 2025.

Key Dates

Keywords

CytoSorbents, earnings release, financial results, DrugSorb-ATR, revenue, gross margin, regulatory approval, cash balance, blood purification, medical device